Abstract
Cystic fibrosis (CF) is caused by mutations in the gene that encodes the cystic fibrosis transmembrane conductance regulator (CFTR) anion channel. In humans and pigs, the loss of CFTR impairs respiratory host defenses, causing airway infection. But CF mice are spared. We found that in all three species, CFTR secreted bicarbonate into airway surface liquid. In humans and pigs lacking CFTR, unchecked H+ secretion by the nongastric H+/K+ adenosine triphosphatase (ATP12A) acidified airway surface liquid, which impaired airway host defenses. In contrast, mouse airways expressed little ATP12A and secreted minimal H+; consequently, airway surface liquid in CF and non-CF mice had similar pH. Inhibiting ATP12A reversed host defense abnormalities in human and pig airways. Conversely, expressing ATP12A in CF mouse airways acidified airway surface liquid, impaired defenses, and increased airway bacteria. These findings help explain why CF mice are protected from infection and nominate ATP12A as a potential therapeutic target for CF.
Athin layer of airway surface liquid (ASL) is the point of contact between an organism and potential pathogens from the environment. To maintain sterile lungs, ASL contains several innate defenses, including a complex mixture of antimicrobials that kill bacteria, mucociliary transport that carries pathogens out of the lung, and phagocytic cells (1–3). In the genetic disease cystic fibrosis (CF) (4, 5), the loss of cystic fibrosis transmembrane conductance regulator (CFTR) impairs airway host defenses, initiating a cascade of bacterial airway infection, inflammation, and progressive destruction (6). After the discovery that mutations in the human CFTR gene cause CF, mice were produced with a disrupted Cftr gene (7, 8). Unexpectedly, airways of CF mice cleared large bacterial inocula and did not develop the spontaneous bacterial infections typical of CF (7, 8). Speculation about why CF mice fail to develop airway infections has relied on correlations. Compared with humans, mice have only a few submucosal glands, have different airway epithelial cell types, express other anion channels, and are smaller—features that correlate with absence of CF-related infections (7–9).
The recent finding that CF pigs develop airway disease that mirrors that of CF in humans (10, 11) provided us with an opportunity to compare humans, pigs, and mice. We reasoned that a better understanding of why CF mice do not develop airway infections might offer new insights into the molecular basis of respiratory infections in humans with CF. A potential mechanism emerged with the discovery that a loss of CFTR-mediated HCO3− secretion and an acidic pH impair at least two airway host defense mechanisms. These defects inhibit the killing of bacteria in ASL (12, 13) (fig. S1). They also alter ASL and mucus viscosity and impede mucociliary transport (14, 15). In addition, they increase mucus viscoelasticity in other organs (16, 17). We therefore explored whether differences between the pH of ASL in humans, pigs, and mice might account for differences in host defense properties. We found that the loss of CFTR reduced ASL pH in differentiated cultures of pig airway epithelia and in vivo, consistent with earlier findings (Fig. 1, A and B) (12). Loss of CFTR also reduced ASL pH in cultures of human airway epithelia (Fig. 1A) (18). In vivo studies of human CF neonates also found a reduced ASL pH (19), although studies of older people with CF yielded variable results (19–21). In contrast, in mice, the loss of CFTR did not reduce ASL pH either in vitro or in vivo (Fig. 1, A and B) (22).
Ca2+-activated Cl− channels might compensate for the loss of CFTR-mediated HCO3− secretion and prevent ASL acidification in CF mice; Ca2+-activated Cl− channels are abundant in mouse but not in human airways (9, 23, 24). Therefore, we predicted that pig airways would exhibit few Ca2+-activated anion channels. We found transcripts for the Ca2+-activated anion channel TMEM16A (anoctamin-1) in CF airway epithelia in a human:pig:mouse ratio of 1:9:18 (Fig. 1C). CF epithelia exhibited Ca2+-stimulated anion secretion in a human:pig:mouse ratio of 1:5:10 (Fig. 1D). Adding carbachol, a Ca2+-mediated secretagogue, elevated ASL pH by 0.02 ± 0.01 units in human, 0.11 ± 0.02 units in pig, and 0.09 ± 0.03 units in mouse epithelia (Fig. 1E). Thus, pig airway epithelia exhibit substantial Ca2+-activated anion secretion, yet they develop airway infections. Although these data do not disprove the proposal that Ca2+-activated anion channels prevent infection in CF mice, they suggest that other factors may be important.
We also reasoned that CF mice might not have an abnormally acidic ASL pH if there was little CFTR in non-CF mouse airways (25). To test CFTR activity, we applied forskolin and IBMX (3-isobutyl-1-methylxanthine) to elevate intracellular cyclic adenosine monophosphate (cAMP) and phosphorylate CFTR. Increasing cAMP stimulated HCO3− secretion in non-CF epithelia of all three species (Fig. 1F) (18, 26, 27). Moreover, stimulating HCO3− secretion elevated ASL pH in non-CF epithelia of all three species (Fig. 1G). These data suggest that the lack of CFTR alone does not explain CF–versus–non-CF differences in ASL pH among species. We expected that without CFTR, cAMP would merely fail to alkalinize ASL; unexpectedly, in CF pig and human epithelia, cAMP stimulation reduced ASL pH (Fig. 1H). In mice, the loss of CFTR prevented cAMP-induced alkalinization, but, in contrast to CF pigs and humans, it did not lower ASL pH.
These results suggest that pigs and humans have a mechanism that acidifies ASL and that this mechanism is absent or less efficient in mice. To focus selectively on H+ secretion, we removed HCO3− and CO2 from the basolateral solution and replaced ASL with a small amount of nonbuffered solution at pH 7. Non-CF pig and human epithelia rapidly acidified the apical solution, whereas non-CF mouse epithelia acidified at about one-sixth the rate (Fig. 2A). CF epithelia yielded similar results (Fig. 2B). Although several epithelial properties influence ASL pH, less H+ secretion in mice is consistent with a higher ASL pH in CF mice than in CF pigs or humans (Fig. 1A).
To determine which transporters secrete H+ in pig airways, we assessed several candidates (28–30). Of the transcripts evaluated, those for ATP12A [the α subunit of the nongastric H+/K+ adenosine triphosphatase (ATPase)] and the a1 and a2 subunits of V-type ATPase were the most abundant in airways, and levels were similar for CF and non-CF pigs (fig. S2). To test for function of H+ secretory proteins, we applied pharmacological inhibitors to the apical surface and found that ouabain, which inhibits ATP12A, increased ASL pH (Fig. 2C and figs. S3 and S4). ASL contains 20 to 40 mM K+ (12), which would be required for ATP12A activity; removing apical K+ prevented H+ secretion (Fig. 2D). Inhibition of ATP12A by small interfering RNA (siRNA) also increased ASL pH, further supporting a role for ATP12A (Fig. 2E and fig. S5A). Previous reports indicate that elevating cAMP stimulates ATP12A activity (31). Consistent with that, apical ouabain and ATP12A siRNA inhibited cAMP-stimulated ASL acidification (fig. S5, B to D). Although ouabain also inhibits the basolateral Na+/K+ ATPase, these effects of apical ouabain did not arise from Na+/K+ ATPase inhibition (fig. S6).
On the basis of these results, we hypothesized that in the absence of CFTR, ATP12A acidifies ASL in pigs and humans, which impairs factors associated with airway defense, but that this process does not occur or is minimal in CF mice. Consistent with these ideas, mouse airways had only 1 to 10% as many ATP12A transcripts (Fig. 2F). Immunohistochemical staining revealed ATP12A at the apical surface of human and pig but not mouse airways (Fig. 2G). ATP12A associates with a β subunit, including the Na+/K+ ATPase β subunit (ATP1B1) (28). Pig and human epithelia showed apical ATP1B1 immunostaining in addition to basolateral staining, whereas in mouse airways, ATP1B1 immunostaining was primarily basolateral (fig. S8). Our hypotheses point to two predictions that can be tested experimentally. The first is that ATP12A is required for ASL acidification and host defense abnormalities in CF pigs. The second is that expressing ATP12A in CF mouse airways would be sufficient to reduce ASL pH and create host defense abnormalities.
To test the first prediction, we inhibited ATP12A with apical ouabain and found that it raised ASL pH in primary cultures of pig airway epithelia (Fig. 3A). We assayed antibacterial activity by briefly touching the ASL with a gold grid coated with Staphylococcus aureus and then determining the percentage of bacteria killed (12). Apical ouabain increased the killing of S. aureus (Fig. 3B). We also assayed ASL viscosity, which is increased in CF and may contribute to impaired mucociliary transport (15, 32). We measured fluorescence recovery after photobleaching (32) and found that apical ouabain reduced viscosity (Fig. 3C). After we applied apical ouabain, the pH, antibacterial activity, and viscosity of CF ASL became similar to those of non-CF ASL.
To test the relevance of these findings in vivo, we studied pigs. We surgically created a small tracheal window and applied ouabain. As observed in vitro, ouabain increased ASL pH and the killing of S. aureus in CF pigs (Fig. 3, D and E). We also measured the effect of apical ouabain on the ASL pH of human epithelia; applying apical ouabain increased ASL pH (Fig. 3F). These data are consistent with a report implicating ATP12A in H+ secretion in human cultures (18). The increase in ASL pH enhanced bacterial killing and reduced ASL viscosity (Fig. 3, G and H). These results suggest that inhibiting ATP12A would also elevate ASL pH in non-CF pigs and humans and improve host defense; supporting this idea, ouabain had similar effects in non-CF as in CF pigs and humans, both in vitro and in vivo (Fig. 3, A to H).
We next tested the second prediction—i.e., that expressing ATP12A in airways of CF mice would decrease ASL pH and generate host defense abnormalities. We treated cultured mouse airway epithelia with an adenovirus encoding ATP12A and found that it acidified ASL (Fig. 4A and figs. S13 to S15). Apical ouabain reversed the effect of ATP12A expression, increasing ASL pH (fig. S16), a result that further supports the conclusion that ATP12A acidifies ASL. ATP12A expression also impaired bacterial killing and increased ASL viscosity in CF mouse epithelia (Fig. 4, B and C).
To test the effects of ATP12A in vivo, we instilled adenovirus expressing ATP12A into the tracheae of CF mice. ATP12A reduced ASL pH and impaired bacterial killing (Fig. 4, D and E). In parallel experiments, expressing ATP12A in non-CF mouse epithelia in vitro and in vivo did not significantly alter ASL pH, bacterial killing, or ASL viscosity (fig. S17, A to F). However, further increasing the amount of vector could reduce ASL pH (fig. S17G).
Finding acidic ASL in CF mice expressing ATP12A suggests that these mice would be predisposed to bacterial infection. The lungs of CF mice expressing ATP12A had 100 times as much bacteria as those of control mice (Fig. 4F). This result is similar to the spontaneous appearance of multiple different bacteria in the lungs of newborn CF pigs (fig. S18) (11, 33). CF mice expressing ATP12A also developed evidence of inflammation; bronchoalveolar lavage revealed elevated numbers of myeloid cells (Fig. 4G and fig. S19). There were also positive correlations between ATP12A mRNA levels and numbers of bacteria and airway macrophages (Fig. 4, H to J).
It has long been puzzling why mice with a disrupted CFTR gene have intact airway host defenses, and it has been hoped that understanding the reason might suggest a therapeutic strategy. Our data provide an explanation. In non-CF pigs and humans, CFTR mediates HCO3− secretion, and ATP12A mediates H+ secretion. The balance between these two secretory processes influences ASL pH. In CF pigs and humans, the loss of CFTR leaves H+ secretion unchecked by HCO3− secretion, ASL pH falls, and the acidic pH and/or the reduced HCO3− concentration impair at least two key ASL properties associated with host defense. Moreover, ASL antimicrobial activity and viscosity are very sensitive to small changes in pH. However, mouse airways express little ATP12A compared with those of pigs and humans. They use V-type ATPase for H+ secretion, but the rate of H+ secretion is low (Fig. 2, A and B, and fig. S20). As a result, the loss of CFTR has minimal effects on ASL pH, and two key ASL defense properties remain largely intact. Other differences between mice, humans, and pigs—such as Ca2+-activated anion channels, the abundance of submucosal glands, and variations in cell types (7–9)—may also contribute to differences in host defense among these species.
Limited ASL acidification in CF mice provides an “experiment of nature” with implications for therapeutics. First, the knowledge that cAMP stimulates ATP12A-mediated H+ secretion (31) and reduces ASL pH might have implications for CF treatments that elevate cAMP levels. For example, β-adrenergic agonists are often prescribed for people with CF to relax airway smooth muscle; although this approach can provide benefit, it seems possible that it might further impair respiratory host defenses. Second, inhibiting ATP12A might have therapeutic value in CF, regardless of CFTR genotype. The findings in mice and the results with apical ouabain in pigs and humans provide a proof of concept.
Supplementary Material
Acknowledgments
This work was funded by NIH (grants HL091842, HL51670, HL117744, F30HL123239, 5T32GM007337, DK054759, and K08HL097071), by the Cystic Fibrosis Foundation (University of Iowa Research Development Program, OSTEDG1410, and STOLTZ14XX0), and by the Roy J. Carver Charitable Trust. D.A.S. was funded by the Gilead Sciences Research Scholars Program in Cystic Fibrosis. M.J.W. is an investigator of the Howard Hughes Medical Institute. We thank J. Engelhardt for mice and D. Bouzek, J.-H. Chen, A. Cooney, N. Gansemer, J. Launspach, T. Mayhew, T. Moninger, C. Parker, S. Ramachandran, N. Sawin, P. Sinn, B. Stein, M. Strub, P. Taft, P. Tan, I. Thornell, L. Vargas, and S. Youtsey (Integrated DNA Technologies) for assistance, support, and advice. The CFTR inhibitor GlyH-101 was a generous gift from Cystic Fibrosis Foundation Therapeutics and R. Bridges. M.J.W. holds equity in Exemplar Genetics, which has licensed CF pigs from the University of Iowa.
Footnotes
REFERENCES AND NOTES
- 1.Cole AM, Dewan P, Ganz T. Infect Immun. 1999;67:3267–3275. doi: 10.1128/iai.67.7.3267-3275.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Wine JJ, Joo NS. Proc Am Thorac Soc. 2004;1:47–53. doi: 10.1513/pats.2306015. [DOI] [PubMed] [Google Scholar]
- 3.Cohen TS, Prince A. Nat Med. 2012;18:509–519. doi: 10.1038/nm.2715. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Quinton PM. Physiol Rev. 1999;79:S3–S22. doi: 10.1152/physrev.1999.79.1.S3. [DOI] [PubMed] [Google Scholar]
- 5.Cutting GR. Nat Rev Genet. 2015;16:45–56. doi: 10.1038/nrg3849. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Stoltz DA, Meyerholz DK, Welsh MJ. N Engl J Med. 2015;372:351–362. doi: 10.1056/NEJMra1300109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Grubb BR, Boucher RC. Physiol Rev. 1999;79:S193–S214. doi: 10.1152/physrev.1999.79.1.S193. [DOI] [PubMed] [Google Scholar]
- 8.Guilbault C, Saeed Z, Downey GP, Radzioch D. Am J Respir Cell Mol Biol. 2007;36:1–7. doi: 10.1165/rcmb.2006-0184TR. [DOI] [PubMed] [Google Scholar]
- 9.Clarke LL, et al. Proc Natl Acad Sci USA. 1994;91:479–483. doi: 10.1073/pnas.91.2.479. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Rogers CS, et al. Science. 2008;321:1837–1841. doi: 10.1126/science.1163600. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Stoltz DA, et al. Sci Transl Med. 2010;2:29ra31. doi: 10.1126/scitranslmed.3000928. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Pezzulo AA, et al. Nature. 2012;487:109–113. doi: 10.1038/nature11130. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Abou Alaiwa MH, et al. Proc Natl Acad Sci USA. 2014;111:18703–18708. doi: 10.1073/pnas.1422091112. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Hoegger MJ, et al. Science. 2014;345:818–822. doi: 10.1126/science.1255825. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Birket SE, et al. Am J Respir Crit Care Med. 2014;190:421–432. doi: 10.1164/rccm.201404-0670OC. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Quinton PM. Lancet. 2008;372:415–417. doi: 10.1016/S0140-6736(08)61162-9. [DOI] [PubMed] [Google Scholar]
- 17.Gustafsson JK, et al. J Exp Med. 2012;209:1263–1272. doi: 10.1084/jem.20120562. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Coakley RD, et al. Proc Natl Acad Sci USA. 2003;100:16083–16088. doi: 10.1073/pnas.2634339100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Abou Alaiwa MH, et al. J Cyst Fibros. 2014;13:373–377. doi: 10.1016/j.jcf.2013.12.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Garland AL, et al. Proc Natl Acad Sci USA. 2013;110:15973–15978. doi: 10.1073/pnas.1311999110. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.McShane D, et al. Eur Respir J. 2003;21:37–42. doi: 10.1183/09031936.03.00027603. [DOI] [PubMed] [Google Scholar]
- 22.Jayaraman S, Song Y, Vetrivel L, Shankar L, Verkman AS. J Clin Invest. 2001;107:317–324. doi: 10.1172/JCI11154. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Caputo A, et al. Science. 2008;322:590–594. doi: 10.1126/science.1163518. [DOI] [PubMed] [Google Scholar]
- 24.Jung J, et al. Proc Natl Acad Sci USA. 2013;110:360–365. doi: 10.1073/pnas.1211594110. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Grubb BR, Paradiso AM, Boucher RCJ. Am J Physiol. 1994;267:C293–C300. doi: 10.1152/ajpcell.1994.267.1.C293. [DOI] [PubMed] [Google Scholar]
- 26.Chen JH, et al. Cell. 2010;143:911–923. doi: 10.1016/j.cell.2010.11.029. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Smith JJ, Welsh MJ. J Clin Invest. 1992;89:1148–1153. doi: 10.1172/JCI115696. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Grishin AV, et al. Semin Nephrol. 1999;19:421–430. [PubMed] [Google Scholar]
- 29.Krouse ME, Talbott JF, Lee MM, Joo NS, Wine JJ. Am J Physiol Lung Cell Mol Physiol. 2004;287:L1274–L1283. doi: 10.1152/ajplung.00036.2004. [DOI] [PubMed] [Google Scholar]
- 30.Fischer H, Widdicombe JH. J Membr Biol. 2006;211:139–150. doi: 10.1007/s00232-006-0861-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Laroche-Joubert N, Marsy S, Michelet S, Imbert-Teboul M, Doucet A. J Biol Chem. 2002;277:18598–18604. doi: 10.1074/jbc.M201868200. [DOI] [PubMed] [Google Scholar]
- 32.Derichs N, Jin BJ, Song Y, Finkbeiner WE, Verkman AS. FASEB J. 2011;25:2325–2332. doi: 10.1096/fj.10-179549. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Stoltz DA, et al. J Clin Invest. 2013;123:2685–2693. doi: 10.1172/JCI68867. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.